Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun;69(2):301-9.
doi: 10.1111/biom.12014. Epub 2013 Feb 14.

Design and estimation for evaluating principal surrogate markers in vaccine trials

Affiliations

Design and estimation for evaluating principal surrogate markers in vaccine trials

Ying Huang et al. Biometrics. 2013 Jun.

Abstract

In vaccine research, immune biomarkers that can reliably predict a vaccine's effect on the clinical endpoint (i.e., surrogate markers) are important tools for guiding vaccine development. This article addresses issues on optimizing two-phase sampling study design for evaluating surrogate markers in a principal surrogate framework, motivated by the design of a future HIV vaccine trial. To address the problem of missing potential outcomes in a standard trial design, novel trial designs have been proposed that utilize baseline predictors of the immune response biomarker(s) and/or augment the trial by vaccinating uninfected placebo recipients at the end of the trial and measuring their immune biomarkers. However, inefficient use of the augmented information can lead to counter-intuitive results on the precision of estimation. To remedy this problem, we propose a pseudo-score type estimator suitable for the augmented design and characterize its asymptotic properties. This estimator has superior performance compared with existing estimators and allows calculation of analytical variances useful for guiding study design. Based on the new estimator we investigate in detail the problem of optimizing the sampling scheme of a biomarker in a vaccine efficacy trial for efficiently estimating its surrogate effect, as characterized by the vaccine efficacy curve (a causal effect predictiveness curve) and by the predicted overall vaccine efficacy using the biomarker.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Vaccine efficacy curves: VE{S(1)} versus S(1). The grey horizontal line is the vaccine efficacy in the population defined as 1 − P(Y = 1|Z = 1)/P(Y = 1|Z = 0). (b) Plot of VEnew(Δ) versus Δ (the location shift in immune response for the refined vaccine versus original vaccine), under the assumption that P [Y = 1|Z = z, S(1) = s] = Φ(β0 + β1z + β2s + β3sz) and P[Y = 1|Znew = z, S(1) = s] = Φ {β0 + β1 + β2s + β3(s + Δ)}.
Figure 2
Figure 2
Efficiency of estimators for various designs as γV varies from 1 to Cost − 1 relative to the design with γV = γP, given fixed Cost = γV + γP, for (a) Cost = 5 and (b) Cost = 10, given ρ = 0.5. Relative Efficiency presented is equal to (variance at γV = γP = Cost/2)/(variance at various γV and γP = CostγV).
Figure 3
Figure 3
Efficiency of estimators for various designs as γV varies from 1 to Cost−1 relative to the design with γV = γP, given fixed Cost = γV + γP = 5 for different linear correlations ρ, for estimating (a) VE{S(1)} and (b) VENew(Δ). Relative Efficiency presented is equal to (variance at γV = γP = Cost/2)/(variance at various γV and γP = CostγV ).

Similar articles

Cited by

References

    1. Burzykowski T, Molenberghs G, Buyse M. The evaluation of surrogate endpoints. Springer; New York: 2005.
    1. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000;1(1):49. - PubMed
    1. Chatterjee N, Chen Y, Breslow N. A pseudoscore estimator for regression problems with two-phase sampling. Journal of the American Statistical Association. 2003;98(461):158–168.
    1. Daniels M, Hughes M. Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine. 1997;16(17):1965–1982. - PubMed
    1. Follmann D. Augmented designs to assess immune response in vaccine trials. Biometrics. 2006;62(4):1161–1169. - PMC - PubMed

Publication types

MeSH terms